Silver Book Fact

Potential savings from shingles vaccine

Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles, post-herpetic neuralgia, and other complications.

Pellesier, James M., Marc Brisson, and Myron J. Levin. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938

Reference

Title
Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
Vaccine
Publication Date
2007
Authors
Pellesier, James M., Marc Brisson, and Myron J. Levin
Volume & Issue
Volume 25, Issue 49
Pages
8326-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Each flu case prevented could save $60 to $4,000
    The influenza vaccination could save between $60 and $4,000 per case prevented.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Savings from flu vaccine
    Vaccination for influenza resulted in an average annual cost savings of $13.66 per healthy working adult vaccinated.  
  • Over 6 years, flu vaccine prevented >110,000 hospitalizations and 5.8 million medical visits
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented more than 110,000 hospitalizations and 5.8 million medical visits.  
  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.